You have read all your free articles, to continue reading subscribe to read the rest of this content.
BioArctic’s lead compound has the potential to become the first disease-modifying treatment for Alzheimer’s, and so far the company’s journey has involved FDA approvals, a successful deal with AbbVie, collaborations with universities – and not least, the hiring of a very dedicated CEO. FoAlready a subscriber Login You have read…
Eugen Steiner has worked in venture capital for 23 years but his roots as a medical doctor still influence the way he nurtures start-ups as a venture partner. “My role as a venture partner [at HealthCap - a family of venture capital funds investing globally in life sciences] is like…
Labiotech.eu has chosen to highlight 20 women they think are making an impact in the European biotech industry, and among them is Carina Schmidt, the CEO of Athera Biotechnologies. Like many technological fields, people with leading roles in big biotech companies have been predominantly male. NoAlready a subscriber Login You have…
Follicum has received approval from the German Medicines Agency (BfArM) and the German Ethics Committee to start a Phase IIa clinical study with a topical formulation of FOL-005 on patients with alopecia (hair loss). The trial will comprise about 200 patients who will be treated with FOL-005 or pAlready a…
